In this article
Some meniscus tears heal without surgery. Whether yours can depends mostly on two things: where the tear sits in the tissue, and what shape it takes. Both are visible on an MRI, which means this is knowable before you agree to an operation.
That distinction matters more than most patients are told. A small tear at the outer rim of the meniscus sits in tissue with its own blood supply and can knit back together. A tear through the inner portion sits in tissue with no direct blood supply at all, and it will not heal on its own no matter how long you wait.
Below is how surgeons read that difference, what the research says about operating, and where cell-based therapy fits for the tears that fall in between.
What the meniscus actually does
The meniscus is a C-shaped wedge of fibrocartilage that sits between the thighbone and the shinbone. There are two in each knee. They spread load across the joint, absorb shock, and keep the knee stable through rotation.
Tears happen two ways. In younger, active people they usually come from a twisting injury with the foot planted. After roughly age 40 they more often appear gradually, as the tissue loses water content and stiffens. Degenerative tears are common in knees that have never hurt a day in their lives, which is part of why an MRI finding alone does not decide the treatment.
Blood supply decides healing potential
Cartilage heals only where blood reaches it. Anatomists divide the meniscus into three zones by vascularity, and this classification drives most surgical decision-making.
| Zone | Location | Blood supply | Healing potential |
|---|---|---|---|
| Red-red | Outer third | Well vascularized | Highest. Many tears here respond to conservative care or repair |
| Red-white | Middle third | Transitional | Intermediate. Depends on tear pattern and patient age |
| White-white | Inner third | Avascular | Low. These tears rarely heal, even after surgical repair |
Only the outer 10% to 30% of the adult meniscus receives direct blood flow. Everything inward of that is fed by joint fluid, which delivers nutrition but not the repair signals that injured tissue needs.
What the research says about operating
For degenerative tears, the evidence for arthroscopic surgery is weaker than most people assume.
In a 2013 sham-controlled trial published in the New England Journal of Medicine, patients with degenerative medial meniscus tears who received arthroscopic partial meniscectomy did no better at twelve months than patients who received a simulated procedure. A separate NEJM trial the same year found physical therapy comparable to surgery in patients over 45 with a meniscal tear and mild-to-moderate osteoarthritis. The ESCAPE trial followed patients out to five years and reported exercise-based physical therapy holding its own against surgery.
Traumatic tears in younger knees have been studied too. A Dutch randomized trial in patients aged 18 to 45 with isolated traumatic tears found that early surgery was not superior to physical therapy with the option of delayed surgery. At 24 months, both groups scored 78 out of 100 on the same function index.
None of this means surgery is the wrong call. Repairable tears should be repaired, and locked knees need to be unlocked. It means the default should be a decision, not a reflex.
Where cell-based therapy fits
Conservative care manages load and rebuilds the muscle that protects the joint. It does not change the biology inside the tear.
That gap is where OmniStem’s joint protocols are aimed. Treatment uses allogeneic UC-MSCs derived from Wharton’s jelly, delivered as a localized, ultrasound-guided knee injection, often alongside PRGF and ozone.
The biological rationale is signaling rather than replacement. UC-MSCs are understood to act mainly through paracrine activity: they release cytokines, growth factors, and extracellular vesicles that modulate the local inflammatory environment. In the red-white and white-white zones, where the tissue’s own repair signals arrive weakly or not at all, this is designed to support the joint environment while rehabilitation does the mechanical work.
This is a complement to structured rehab, not a replacement for surgery in tears where the tissue cannot hold. If a physician on the medical team reads your imaging and concludes you need an operation, that is what you will hear during the consultation.
Who tends to be a candidate
You may be an appropriate candidate if:
- Your tear is small to moderate, longitudinal or horizontal, in the red-red or red-white zone
- Your knee does not lock, catch, or give way
- You have completed a course of conservative care and want to go further before considering surgery
- You have joint pain alongside early degenerative change rather than an acute mechanical block
- You are well enough to travel for a short treatment stay
Bucket-handle tears, displaced fragments, and any knee that locks are usually better served by surgical evaluation first. Cell-based therapy after a repair is a separate conversation and one the medical team is happy to have.
How treatment is structured
1. Case review. You share imaging, history, and goals. Dr. Montoya or another physician on the medical team reviews the case individually and returns an initial assessment. If you are not a candidate, you are told before you book a flight.
2. Treatment in Punta Cana. A single-joint protocol runs one day. The biologic is produced in OmniStem’s own laboratory in the same building where it is administered, under Ministry of Health authorization, and released only after testing for sterility, viability, and identity. You depart with the Certificate of Analysis for your batch: preparation date, cell count, viability percentage, and the name of the scientist who released it.
3. Follow-up. Recovery is tracked remotely, usually alongside physical therapy at home.
Punta Cana International is a 90-minute flight from Miami, with direct service from most of the Eastern Seaboard.
What recovery generally looks like
Weeks 1 to 2. Swelling is managed. Imaging confirms zone and pattern. The injection is delivered once candidacy is confirmed.
Weeks 3 to 6. Physical therapy typically begins with straight-leg raises and low-impact quadriceps work, avoiding deep flexion that loads the healing tissue.
Months 2 to 3. Therapy progresses to closed-chain strengthening, controlled extensions, and light squats to restore dynamic stability.
Months 3 to 6 and beyond. Function is reassessed against your normal activity demands.
This is a general pattern rather than a prediction. Timelines vary by tear zone, tear pattern, age, and how consistently rehabilitation is followed. Clinical response varies by individual.
Cost
A single-joint UC-MSC and exosome protocol at OmniStem ranges from $5,200 to $6,500 USD, which includes the localized injection, PRGF and ozone, HBOT, a physiotherapy assessment, and follow-up. Final investment is confirmed after medical evaluation and protocol design. Financing is available for patients who qualify.
Common questions
Start with a medical evaluation
Your case begins with a physician reading your imaging, not a sales call.
Educational material only. This article does not replace individualized medical advice, diagnosis, informed consent, or treatment by a qualified physician. Regenerative therapies require medical evaluation. Outcomes vary by patient, condition, and protocol. OmniStem does not diagnose, treat, cure, or guarantee reversal of any disease or symptom.
